Glaser Sherrye T, Kaczocha Martin, Deutsch Dale G
Medical Department, Brookhaven National Laboratory, Upton, New York 11973, United States.
Life Sci. 2005 Aug 19;77(14):1584-604. doi: 10.1016/j.lfs.2005.05.007.
Anandamide (AEA) uptake has been described over the last decade to occur by facilitated diffusion, but a protein has yet to be isolated. In some cell types, it has recently been suggested that AEA, an uncharged hydrophobic molecule, passively diffuses through the plasma membrane in a process that is not protein-mediated. Since that observation, recent kinetics studies (using varying assay conditions) have both supported and denied the presence of an AEA transporter. In this review, we analyze the current literature exploring the mechanism of AEA uptake and endeavor to explain the reasons for the divergent views. One of the main variables among laboratories is the incubation time of the cells with AEA. Initial kinetics (at time points <1 min depending upon the cell type) isolate events that occur at the plasma membrane and are most useful to study saturability of uptake and effects of purported transport inhibitors upon uptake. Results with longer incubation times reflect events not only at the plasma membrane but also interactions at intracellular sites that may include enzyme(s), other proteins, or specialized lipid-binding domains. Furthermore, at long incubation times, antagonists to AEA receptors reduce AEA uptake. Another complicating factor in AEA transport studies is the nonspecific binding to plastic culture dishes. The magnitude of this effect may exceed AEA uptake into cells. Likewise, AEA may be released from plastic culture dishes (without cells) in such a manner as to mimic efflux from cells. AEA transport protocols using BSA, similar to the method used for fatty acid uptake studies, are gaining acceptance. This may improve AEA solution stability and minimize binding to plastic, although some groups report that BSA interferes with uptake. In response to criticisms that many transport inhibitors also inhibit the fatty acid amide hydrolase (FAAH), new compounds have recently been synthesized. Following their characterization in FAAH+/+ and FAAH-/- cells and transgenic mice, several inhibitors have been shown to have physiological activity in FAAH-/- mice. Their targets are now being characterized with the possibility that a protein transporter for AEA may be characterized.
在过去十年中,已证明花生四烯乙醇胺(AEA)通过易化扩散被摄取,但尚未分离出相关蛋白。最近有研究表明,在某些细胞类型中,呈电中性的疏水分子AEA会以非蛋白质介导的方式被动扩散通过质膜。自该发现以来,近期的动力学研究(采用不同的测定条件)对AEA转运体的存在既有支持的观点,也有否定的观点。在本综述中,我们分析了探索AEA摄取机制的当前文献,并力图解释观点分歧的原因。各实验室之间的一个主要变量是细胞与AEA的孵育时间。初始动力学(根据细胞类型,时间点<1分钟)分离出质膜上发生的事件,这对于研究摄取的饱和性以及所谓的转运抑制剂对摄取的影响最为有用。较长孵育时间的结果不仅反映了质膜上的事件,还反映了细胞内位点的相互作用,这些位点可能包括酶、其他蛋白质或特殊的脂质结合结构域。此外,在较长孵育时间下,AEA受体拮抗剂会降低AEA摄取。AEA转运研究中的另一个复杂因素是其与塑料培养皿的非特异性结合。这种效应的程度可能超过AEA摄取进入细胞的量。同样,AEA可能会以模拟从细胞外流的方式从(无细胞的)塑料培养皿中释放出来。使用牛血清白蛋白(BSA)的AEA转运方案,类似于用于脂肪酸摄取研究的方法,正逐渐被接受。这可能会提高AEA溶液的稳定性,并使与塑料的结合最小化,尽管一些研究小组报告称BSA会干扰摄取。针对许多转运抑制剂也会抑制脂肪酸酰胺水解酶(FAAH)的批评,最近合成了新的化合物。在对FAAH+/+和FAAH-/-细胞以及转基因小鼠进行表征后,几种抑制剂已被证明在FAAH-/-小鼠中具有生理活性。目前正在对它们的靶点进行表征,有可能鉴定出AEA的蛋白质转运体。